Observing Bempedoic Acid and Ezetimibe Use in Adults with High Cholesterol
Observes real-world use of bempedoic acid, alone or with ezetimibe, in adults with high cholesterol.
Plain-language title generated from the registry record
Registry title: A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
Key facts
- Where
- Belo Horizonte, Blumenau, Caixias Do Sul, Campina Grande do Sul, Curitiba, Joinville, Juiz de Fora, Maringá, Pocos de Calda, Porto Alegre, Salvador, Santo André, São Paulo, and Tatuí, BrazilSee the 23 sites
Where in Brazil
- Hospital Felicio RochoBelo Horizonte, BrazilTaking people
- Hospital Mater Dei ContornoBelo Horizonte, BrazilTaking people
- Hospital Vera CruzBelo Horizonte, BrazilTaking people
- Clinica Procardio Ltda.Blumenau, BrazilTaking people
- Universidade de Caxias do Sul (UCS)Caixias Do Sul, BrazilTaking people
- Hospital e Maternidade Angelina CaronCampina Grande do Sul, BrazilTaking people
- Pontificia Universidade Catolica do Parana-(PUCPR)Curitiba, BrazilTaking people
- CMEP Centro Multidisciplinar de Ensino Especializado e Pesquisa LtdaJoinville, BrazilTaking people
- Galileo Medical Research Ltda.Juiz de Fora, BrazilTaking people
- Hospital Parana - Parana Medical Research CenterMaringá, BrazilTaking people
- Hospital Maternidade e Pronto Socorro Santa LuciaPocos de Calda, BrazilTaking people
- Hospital Moinhos de Vento (HMV)Porto Alegre, BrazilTaking people
- Fundação Bahiana de InfectologiaSalvador, BrazilTaking people
- Hospital da Mater Dei SalvadorSalvador, BrazilTaking people
- Hospital E Maternidade Dr. Cristavao da Gama (HMCG)Santo André, BrazilTaking people
- BP - A Beneficência Portuguesa de São PauloSão Paulo, BrazilTaking people
- Cardial Servicos Medicos EspecializadosSão Paulo, BrazilTaking people
- FGM Clinica Paulista De Doencas Cardiovasculares (IPDC)São Paulo, BrazilTaking people
- Hospital Alemao Oswaldo Cruz (HAOC)São Paulo, BrazilTaking people
- Instituto Conceive LtdaSão Paulo, BrazilTaking people
- Instituto do Coração do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - InCor HCFMUSPSão Paulo, BrazilTaking people
- Universidade de Sao Paulo (USP) - Hospital das Clinicas da Faculdade de MedicinaSão Paulo, BrazilTaking people
- Instituto de Moléstias Cardiovasculares TatuíTatuí, BrazilTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Daiichi Sankyo
- Trial code
- NCT07206472
- Record updated
- 19 October 2026
- Original description
There is limited efficacy and safety data of bempedoic acid or its fixed dose combination (FDC) with ezetimibe in Asian and Latin American patients. This non-interventional study (NIS) will be conducted to characterize the risks and benefits of bempedoic acid or FDC with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.Read full original descriptionShow less
A Multi-national, Non-interventional Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia
There is limited efficacy and safety data of bempedoic acid or its fixed dose combination (FDC) with ezetimibe in Asian and Latin American patients. This non-interventional study (NIS) will be conducted to characterize the risks and benefits of bempedoic acid or FDC with ezetimibe in a real-world clinical setting in adult patients with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia.
Patients can be enrolled, when they fulfil the following inclusion criteria:; Written informed consent to participate; At least 18 years of age; Patients suffering from documented primary hypercholesterolemia or mixed dyslipidaemia treated or intended to be treated with bempedoic acid/ FDC with ezetimibe at the discretion of the physician are appropriate for participation in the observation; For patients who are treated with bempedoic acid/FDC with ezetimibe prior to signed informed consent, initiation of bempedoic acid/FDC with ezetimibe must be within a maximum of three months prior to inclusion; No contraindications exist according to the SmPC of bempedoic acid/FDC with ezetimibe; No concurrent participation in an interventional study (simultaneous participation in other non-interventional study is possible); Life expectancy > 1 year; No explicit exclusion criteria exist to avoid selection bias and to allow for documentation of routine clinical practice.